Pulsenmore Expands U.S. Presence with New Home Ultrasound Partnership
Summary
Pulsenmore Ltd. announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine practice in Maryland, to integrate its home ultrasound services into their care model, marking continued U.S. expansion.
Key Events
-
Secures New U.S. Commercial Engagement
Pulsenmore entered a services agreement with TLC Perinatal PA in Maryland to integrate its Early Screening (ES) home ultrasound services.
-
Expands U.S. Market Rollout
This marks another step in the company's growing U.S. commercial operations, following its initial engagement earlier this month on 2026-02-02 and recent Nasdaq registration on 2026-01-27.
-
Validates Hybrid Care Model
The partnership will allow patients to perform ultrasound scans at home as part of a physician-directed hybrid care pathway, enhancing access and convenience.
Analysis
This filing highlights Pulsenmore's continued momentum in the U.S. market following its recent FDA clearance and initial commercial engagement. The partnership with TLC Perinatal PA, a specialized maternal-fetal medicine practice, demonstrates increasing adoption of Pulsenmore's home ultrasound technology. This expansion is crucial for the company's growth strategy, validating its patient-centric approach and extending prenatal care access through a hybrid care pathway. Investors should view this as a positive step in the company's U.S. rollout, indicating successful execution and market penetration.
At the time of this filing, PLSM was trading at $5.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $37.4M. The 52-week trading range was $5.57 to $10.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.